# Opus reports sustained vision gains as LCA5 gene therapy moves toward Phase 3 dosing

_Published Friday, October 16, 2026 at 9:18 AM EDT · Science · Latest · Tier 2 — Notable_

![Opus reports sustained vision gains as LCA5 gene therapy moves toward Phase 3 dosing — Primary](https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg)

Opus Genetics reported sustained visual improvements in six participants receiving its experimental OPGx-LCA5 gene therapy, with follow-up through 24 months in three adults and six months in three adolescents. Presenting at Retina in Rio, the company said its Phase 3 natural history and treatment cohorts were fully enrolled, with dosing expected in the fourth quarter of 2026.

The therapy delivers a functional LCA5 gene to retinal light-sensitive cells to restore production of lebercilin, a protein needed for normal retinal function. Opus advanced the low dose into Phase 3 without further dose escalation. The findings remain interim, and the company cautioned that initial results may not predict final trial outcomes.

## Sources

- [Markets Insider](https://markets.businessinsider.com/news/stocks/opus-genetics-presents-positive-clinical-data-from-opgx-best1-and-opgx-lca5-gene-therapy-programs-at-retina-in-rio-2026-1036631973)

---
Canonical: https://techandbusiness.org/newswire/zeSoRaMFGO9fM7Vrea3IUu
Published: 2026-10-16T13:18:19.810Z
Story chronology: 2026-10-15T22:00:00.000Z
Retrieved: 2026-10-16T17:01:11.043Z
Publisher: Tech & Business (techandbusiness.org)